Prospective Surveillance of Respiratory Infections in British Antarctic Survey Bases During the COVID-19 PandemicArticle Published on 2022-12-132023-07-10 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), [키워드] Antarctic imported Infection personnel respiratory virus SARS-CoV-2 Surveillance symptomatic Transmission. [DOI] 10.1093/infdis/jiac412 PMC 바로가기
Vaccine effectiveness and duration of protection against symptomatic infections and severe Covid-19 outcomes in adults aged 50 years and over, France, January to mid-December 2021Research article Published on 2022-12-012022-10-05 Journal: Global Epidemiology [Category] 변종, [키워드] Analysis booster booster dose COVID-19 database deaths decrease delta variant Effectiveness ENhance Evolution finding France Hospitalization hospitalizations ICU admission infected individuals information National outcome performed Real-world estimates reduced remained reversed SARS-CoV-2 Spread survival symptomatic symptomatic infection symptomatic infections test-negative design vaccination Vaccine vaccine immunity variant variants waning immunity [DOI] 10.1016/j.gloepi.2022.100076 [Article Type] Research article
Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19코로나19 중증도에 따라 항체 표적 SARS-CoV-2 에피토프 레퍼토리 달라Article Published on 2022-12-012022-09-11 Journal: Virulence [Category] COVID19(2023년), SARS, 진단, 치료법, [키워드] antibodies antibody Antigen association Asymptomatic asymptomatic individual asymptomatic infection Betacoronavirus betacoronavirus Community convalescent correlated COVID-19 COVID-19 severity develop diagnosed diagnostics disease severity domains Epitopes Evidence evidence of finding FIVE five groups HKU1 Hospitalization IgG IgGs Immunity immunogenic immunogenic peptide individual Infection less MERS-CoV nucleocapsid protein Nucleocapsid proteins OC43 participant pathogenic pathogenic mechanisms peptide peptide array peptides pilot study predicted Protein RBDs reaction Receptor binding domain Region repertoire SARS-CoV RBD SARS-CoV RBDs SARS-CoV-2 SARS-CoV-2 epitope SARS-CoV-2 epitopes seroconverted Seroprevalence seroprevalence. severity severity of COVID-19 symptomatic symptomatic COVID-19 symptomatic infection therapeutic therapeutic antibodies Vaccines Viral with COVID-19 without symptoms [DOI] 10.1080/21505594.2022.2073025 PMC 바로가기 [Article Type] Article
COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia말레이시아에서 BNT162b2 백신을 접종한 의료 종사자의 COVID-19 획기적인 감염 및 체액성 면역 반응Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] 95% CI affected age Anti-S1 Anti-spike antibody Antibody Response antibody titres association Asymptomatic Asymptomatic individuals blood sample Blood samples BNT162b2 booster vaccination breakthrough Breakthrough infection breakthrough infections collected COVID-19 COVID-19 infection delta variant detectable domain geometric mean geometric mean titre GMT HCWs healthcare healthcare worker Healthcare workers humoral humoral immune response Humoral immunity IgG IgG assay individual individuals Infection investigated Malaysia not different notable outcome Participants prospective cohort study Protein response significantly significantly higher Support symptomatic the antibody response vaccination Vaccine vaccine doses vaccine. waned was measured [DOI] 10.1080/22221751.2022.2065936 PMC 바로가기 [Article Type] Article
An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variantsSARS-CoV-2 오미크론 변이체에 감염된 중국 참가자의 VV116에 대한 공개, 전향적 코호트 연구Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] adjusted administration adverse event adverse events anti-SARS-CoV-2 antiviral drug baseline characteristics Chinese Cohort cohort study collected conducted control group COVID-19 Cox regression analysis effective Effectiveness Efficacy enrolled evaluate first positive Follow-up Hospitalized infected with SARS-CoV-2 Infection Intervention median time no significant difference omicron Omicron variant participant Patient preclinical studies predominant Prevalence prospective cohort study receive regression analysis reported resolved robust Safe Serious Adverse Event Serious Adverse Events standard treatment Symptom symptomatic treatment group variant variant of SARS-CoV-2 Viral load Viral load. viral shedding VV116 with COVID-19 [DOI] 10.1080/22221751.2022.2078230 PMC 바로가기 [Article Type] Article
The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis후속 SARS-CoV-2 감염에 대한 자연 획득 항체의 보호: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Acquired Against analyses analysis antibody asymptomatic infection conducted COVID-19 COVID-19 case COVID-19 infection COVID-19 vaccination Efficacy eligible General population HCWs Health care worker incidence rate individual Infection Meta-analysis Naturally naturally acquired antibody naturally acquired immunity Newcastle-Ottawa Scale NOS Older outcome Population programming protection provided reduce Registration Reinfection reinfection. review risk SARS-CoV-2 SARS-COV-2 infection searched seropositive significant difference significantly specific antibody subsequent symptomatic was used [DOI] 10.1080/22221751.2022.2046446 PMC 바로가기 [Article Type] Meta-Analysis
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control studyArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] 95% CI adjusted hazard ratio Antiviral antiviral. ARMS clinical clinical condition Clinical improvement complications control arm COVID-19 COVID-19 patient Day defined early treatment Effect Efficacy enrolled enrolment faster Favipiravir female FPV investigated likelihood median median time mild case mild pneumonia multicentre Patient PCR-confirmed Pneumonia primary endpoint randomized control study RdRP RdRp inhibitor registry risk of COVID-19 SARS-CoV-2-infected patient score significantly higher supportive care sustained symptomatic Thailand Treatment viral clearance Viral detection [DOI] 10.1080/22221751.2022.2117092 PMC 바로가기
Pregnancy outcomes among symptomatic and asymptomatic women infected with COVID-19 in the west of Iran: a case-control studyArticle Published on 2022-12-012023-07-06 Journal: The journal of maternal-fetal & neonatal medicine [Category] COVID19(2023년), SARS, [키워드] Asymptomatic case-control. coronavirus pregnancy outcomes symptomatic [DOI] 10.1080/14767058.2020.1861599 PMC 바로가기
Effects of the Omicron variant on perinatal outcomes in full-term neonatesArticle Published on 2022-11-032022-11-16 Journal: BMC Pediatrics [Category] SARS, 변종, [키워드] absence analyzed APGAR score complications conducted coronavirus disease COVID COVID-19 criteria demonstrated Effect enrolled exclusion criteria Full-term neonate Infection investigated Isolation Korean Mortality mother Neonatal resuscitation Neonate Newborn non-infectious omicron Omicron variant outcome outcomes Perinatal Perinatal outcomes. Pregnancy required Research Respiratory Support Self-isolation Seven significant difference single center symptomatic symptomatic and asymptomatic tachypnea variant were excluded [DOI] 10.1186/s12887-022-03690-8 PMC 바로가기
Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseasesArticle Published on 2022-11-022022-11-15 Journal: Rheumatology (Oxford, England) [Category] SARS, 진단, 치료기술, [키워드] adverse event childhood-onset rheumatic disease Chinese Cohort COVID-19 COVID-19 infection cPass™ cut-off defined disease Disease activity dose Efficacy evaluate female first vaccination humoral immunogenicity immunogenicity increased the risk inhibition median medication Most patient mounted mRNA vaccination mRNA vaccine neutralization Neutralizing antibodies Neutralizing antibody response neutralizing response not affect Paediatric age paediatric rheumatology Patient positive predictor proportion remained response rheumatic disease SARS-CoV-2 SARS-CoV-2 vaccine second vaccination Serious Adverse Event serious complication Seven Subgroup analysis symptomatic the SARS-CoV-2 the vaccine two-dose regimen vaccination Vaccine vaccine efficacy vaccine safety. were assessed [DOI] 10.1093/rheumatology/keac105 PMC 바로가기